Src-FAK Signaling Mediates Interleukin 6-Induced HCT116 Colorectal Cancer Epithelial-Mesenchymal Transition

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide.
• Elevated serum interleukin-6 (IL-6) correlates with advanced CRC and poor prognosis.
• The precise mechanisms of IL-6-induced epithelial-mesenchymal transition (EMT) in CRC remain incompletely understood.

Purpose of the Study:

• To investigate the regulatory role of IL-6 signaling in CRC epithelial-mesenchymal transition (EMT).
• To elucidate the molecular pathways involved in IL-6-mediated EMT in colorectal cancer cells.

Main Methods:

• Utilized HCT116 human colorectal cancer cells for experimental analysis.
• Assessed changes in epithelial and mesenchymal markers (E-cadherin, vimentin, α-SMA) and EMT regulators (Twist, Snail, Slug).
• Investigated the activation of signaling pathways including Src, FAK, ERK1/2, p38MAPK, STAT3, NF-κB, and C/EBPβ.

Main Results:

• IL-6 treatment reduced E-cadherin expression and increased mesenchymal markers and EMT regulators in HCT116 cells.
• IL-6 induced the activation of Src, FAK, ERK1/2, p38MAPK, STAT3, NF-κB, and C/EBPβ.
• IL-6 promoted the recruitment of STAT3, NF-κB, and C/EBPβ to the Twist promoter.
• Blocking Src-FAK signaling attenuated IL-6-induced pathway activation and reversed the mesenchymal phenotype.

Conclusions:

• IL-6 activates the Src-FAK-ERK/p38MAPK signaling cascade, leading to EMT in colorectal cancer cells.
• Targeting Src-FAK signaling presents a potential therapeutic strategy to inhibit CRC progression.